<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00752960</url>
  </required_header>
  <id_info>
    <org_study_id>R44MH073291</org_study_id>
    <secondary_id>50R44 MH073291-03</secondary_id>
    <nct_id>NCT00752960</nct_id>
  </id_info>
  <brief_title>DNA Diagnostics for Minimizing Metabolic Side-Effects of Antipsychotics</brief_title>
  <acronym>DIMS</acronym>
  <official_title>DNA Diagnostics for Minimizing Metabolic Side-Effects of Antipsychotics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genomas, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hartford Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Kentucky</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Genomas, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess patients treated with the antipsychotics aripiprazole
      (Abilify®), olanzapine (Zyprexa®), quetiapine (Seroquel®), risperidone (Risperdal®), or
      ziprasidone (Geodon®) and to identify genetic variations more commonly found in individuals
      who develop diabetic metabolic signs and symptoms, which include changes in blood lipids,
      blood glucose, blood pressure, and body weight.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      As many as 30% of psychiatric patients experience weight gain, central deposition of fat,
      dyslipidemia, increased blood glucose and hypertension--diabetic metabolic symptoms--upon
      treatment with atypical antipsychotic medication. As a result, cardiovascular disease risk is
      significantly increased.

      The long-term goal of this collaborative study is to identify, for each individual atypical
      antipsychotic (AAP) medication, the gene variations associated with elevated risk of diabetic
      metabolic symptoms (DiMS). If such genes are identified, in the future genetic testing may
      help mental health care professionals choose treatment while minimizing the risk of
      undesirable side effects of antipsychotics. We propose to develop a novel product termed
      &quot;Physiotype&quot; to deliver personalized information for each patient on the drug specific risks
      among aripiprazole, olanzapine, quetiapine, risperidone, and ziprasidone. The Physiotype
      consists of a multi-gene ensemble of single nucleotide polymorphisms (SNPs) that, interpreted
      with a biomathematical algorithm, may explain most of the inter-individual differences in
      DiMS among the 5 AAPs. If this study does identify related genes, genetic tests will be
      developed to provide patients and health care professionals with tools to identify those
      patients who are at risk of developing adverse metabolic side effects to antipsychotics.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2007</start_date>
  <completion_date type="Anticipated">December 2009</completion_date>
  <primary_completion_date type="Anticipated">December 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>diabetic metabolic symptoms (DiMS): body weight, body mass index, waist circumference, blood pressure, triglycerides, total, LDL, and HDL cholesterol, blood glucose</measure>
    <time_frame>after treatment with antipsychotic medication(s) for =&gt; 3 months</time_frame>
  </primary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Psychoses</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <description>Patients receiving olanzapine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <description>patients receiving risperidone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <description>Patients receiving quetiapine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D</arm_group_label>
    <description>Patients receiving aripiprazole</description>
  </arm_group>
  <arm_group>
    <arm_group_label>E</arm_group_label>
    <description>patients receiving ziprasidone</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      DNA extracted from whole blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients treated for psychoses
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  receiving atypical antipsychotic therapy (olanzapine, aripiprazole, quetiapine,
             risperidone, or ziprasidone) for 3 months

          -  who have taken &gt;50% of the prescribed dose for the last month.

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gualberto Ruano, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Genomas, Inc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Steven Woolley, PhD</last_name>
    <phone>860-545-7329</phone>
    <email>swoolle@harthosp.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hartford Hospital Institute of Living</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven Woolley, PhD</last_name>
      <phone>860-545-7329</phone>
      <email>Swoolle@harthosp.org</email>
    </contact>
    <contact_backup>
      <last_name>John D. Goethe, MD</last_name>
      <phone>860-545-7118</phone>
      <email>jgoethe@harthosp.org</email>
    </contact_backup>
    <investigator>
      <last_name>John W Goethe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40508</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose de Leon, MD</last_name>
      <phone>859-246-7563</phone>
      <email>jdeleon@uky.edu</email>
    </contact>
    <investigator>
      <last_name>Jose de Leon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.instituteofliving.org/</url>
    <description>Institute of Living, Hartford Hospital, Hartford, CT</description>
  </link>
  <reference>
    <citation>Ruaño G, Blair CL, Bower B, Windemuth A, Kocherla M, Aleman Y, Pearlson G, Goethe JW, Schwartz HI. Somatic complications of psychotropic medications in a patient with multiple CYP2 drug metabolism deficiencies. Conn Med. 2007 Apr;71(4):197-200.</citation>
    <PMID>17487003</PMID>
  </reference>
  <reference>
    <citation>de Leon J, Susce MT, Johnson M, Hardin M, Pointer L, Ruaño G, Windemuth A, Diaz FJ. A clinical study of the association of antipsychotics with hyperlipidemia. Schizophr Res. 2007 May;92(1-3):95-102. Epub 2007 Mar 8.</citation>
    <PMID>17346932</PMID>
  </reference>
  <reference>
    <citation>Ruaño G, Goethe JW, Caley C, Woolley S, Holford TR, Kocherla M, Windemuth A, de Leon J. Physiogenomic comparison of weight profiles of olanzapine- and risperidone-treated patients. Mol Psychiatry. 2007 May;12(5):474-82. Epub 2007 Jan 2.</citation>
    <PMID>17199131</PMID>
  </reference>
  <verification_date>September 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2008</study_first_submitted>
  <study_first_submitted_qc>September 12, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2008</study_first_posted>
  <last_update_submitted>September 12, 2008</last_update_submitted>
  <last_update_submitted_qc>September 12, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 16, 2008</last_update_posted>
  <responsible_party>
    <name_title>Gualberto Rauno, MD, PhD/President</name_title>
    <organization>Genomas, Inc.</organization>
  </responsible_party>
  <keyword>single nucleotide polymorphism, SNP, aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone, metabolic syndrome</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antipsychotic Agents</mesh_term>
    <mesh_term>Aripiprazole</mesh_term>
    <mesh_term>Ziprasidone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

